World News: 11:03 GMT Wednesday 14th August 2019. [Coloplast A/S via Globe Newswire via SPi World News]
“We see strong performance in Europe driven by all business areas, double-digit growth in the US, and improved momentum in Emerging Markets driven by solid performance in China. Finally, I would like to highlight our 8% organic growth, year to date, in our Wound Care business and our double-digit growth, year to date, in the Interventional Urology business,” says CEO Kristian Villumsen, Coloplast, and continues:
“We deliver solid growth rates across all business areas, driven by our product launches and commercial investments, and we continue to invest in commercial initiatives to drive future growth.”
Organic growth rates by business area in the third quarter were 8% in Ostomy Care, 7% in Continence Care, 10% in Interventional Urology, and 7% in Wound & Skin Care.
Looking at sales by geographies in the third quarter, the European markets contributed with 5% growth, Other developed markets delivered 12% revenue growth, and Emerging Markets provided a 14% increase.
EBIT amounted to DKK 4,077m for the first nine months, an 11% increase in DKK, corresponding to an EBIT margin of 31% against 30% last year. ROIC after tax before special items was 45% in the first nine months against 42% in the same period last year.
Globe Newswire: 11:03 GMT Wednesday 14th August 2019
SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.